
Organoids Market Report 2026
Global Outlook – By Product (Hepatic Organoid, Colorectal Organoid, Intestinal Organoid, Other Products), By Application (Developmental Biology, Disease Pathology Of Infectious Disease, Regenerative Medicine, Drug Toxicity And Efficacy Testing, Drug Discovery And Personalized Medicine, Other Applications), By End-User (Hospitals And Diagnostic Centers, Biotechnology And Pharmaceutical Companies, Other End-Users) - Market Size, Trends, And Global Forecast 2026-2035
Organoids Market Overview
• Organoids market size has reached to $4.82 billion in 2025 • Expected to grow to $13.13 billion in 2030 at a compound annual growth rate (CAGR) of 22.2% • Growth Driver: Increase In Chronic And Infectious Diseases Spurs Growth Of Organoid Market • Market Trend: Revolutionary Platform To Accelerate Preclinical Oncology Drug Discovery • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.What Is Covered Under Organoids Market?
Organoids refer to three-dimensional and tiny tissue cultures derived from stem cells. Organoids are used for customized, regenerative medicine, gene repair, and transplantation therapy. The main products of organoids are hepatic organoids, colorectal organoids, intestinal organoids, and others. Hepatic organoid refers to three-dimensional in vitro models of the liver that are functional. Hepatic organoids are used to address the various research questions related to hepatic development and regeneration, disease modeling, and others. The various sources of organoids include pluripotent stem cells and organ-specific adult stem cells that are typically applied in developmental biology, disease pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. These are used by hospitals and diagnostic centers, biotechnology and pharmaceutical companies, and others.
What Is The Organoids Market Size and Share 2026?
The organoids market size has grown exponentially in recent years. It will grow from $4.82 billion in 2025 to $5.9 billion in 2026 at a compound annual growth rate (CAGR) of 22.3%. The growth in the historic period can be attributed to advancements in stem cell technology, rising demand for alternative models to animal testing, increasing research in tissue engineering, growing investments in biotechnology R&D, early adoption of organoid models by academic research institutes.What Is The Organoids Market Growth Forecast?
The organoids market size is expected to see exponential growth in the next few years. It will grow to $13.13 billion in 2030 at a compound annual growth rate (CAGR) of 22.2%. The growth in the forecast period can be attributed to expansion of personalized medicine applications, increasing pharmaceutical industry collaborations with organoid research companies, growth in regenerative medicine initiatives, rising government and private funding for organoid-based research, development of organoid biobanks for disease modeling. Major trends in the forecast period include rising adoption of organoids in drug discovery and personalized medicine, increasing use of organoids in regenerative medicine and tissue engineering, growing applications of organoids in infectious disease pathology studies, increasing development of disease-specific organoids for targeted therapeutics, rising integration of organoid models in preclinical drug efficacy and toxicity testing.Global Organoids Market Segmentation
1) By Product: Hepatic Organoid, Colorectal Organoid, Intestinal Organoid, Other Products 2) By Application: Developmental Biology, Disease Pathology Of Infectious Disease, Regenerative Medicine, Drug Toxicity And Efficacy Testing, Drug Discovery And Personalized Medicine, Other Applications 3) By End-User: Hospitals And Diagnostic Centers, Biotechnology And Pharmaceutical Companies, Other End-Users Subsegments: 1) By Hepatic Organoid: Hepatic Stem Cell-Derived Organoids, Primary Liver Cell-Derived Organoids, Liver Tumor Organoids 2) By Colorectal Organoid: Colonic Organoids, Rectal Organoids, Colorectal Cancer Organoids 3) By Intestinal Organoid: Small Intestinal Organoids, Enteroid Organoids, Intestinal Stem Cell-Derived Organoids 4) By Other Products: Pancreatic Organoids, Brain Organoids, Kidney Organoids, Lung OrganoidsWhat Is The Driver Of The Organoids Market?
An increase in the incidence and prevalence of chronic and infectious diseases is expected to propel the growth of the organoid market going forward. Chronic disease is a condition that lasts more than a year and requires ongoing medical treatment. Organoids have been used to study various chronic diseases and their treatments as they give immediate and dependable information on pathogen biology and drug screening. Hence, the increase in the incidence and prevalence of chronic and infectious diseases will support the organoid market. For instance, in June 2024, according to the National Health Service, a UK-based publicly funded healthcare system, there were 3,615,330 people registered with a GP who were found to have non-diabetic hyperglycemia also known as pre-diabetes, in 2023, compared to 3,065,825 in 2022 an increase of almost a fifth (18%). Therefore, the rising prevalence of chronic diseases will drive the organoids industry.Key Players In The Global Organoids Market
Major companies operating in the organoids market are Cellesce Ltd., STEMCELL Technologies, HUB Organoids, DefiniGEN, OcellO B.V., Organoid Therapeutics, InSphero AG, Axol Bioscience Ltd., TissUse GmbH, Epithelix Sàrl, SUN Bioscience, Prellis Biologics, Epistem, MIMETAS BV, Organoidsciences Ltd., Zenit Science, Biomorgan, TheWell Bioscience Inc., CN Bio Innovations Ltd., TARA Biosystems, Nortis Inc., Newcells Biotech, Known Medicine, Dynomics Inc., CHA Biotech Co Ltd, Tempus AI Inc.Global Organoids Market Trends and Insights
Major companies in the organoids market are focusing on developing revolutionary platforms, such as organoid panel screening platforms, to accelerate preclinical oncology drug discovery and gain a competitive edge in the market. An organoid panel screening platform refers to a system that allows the screening of a collection of organoids. For instance, in November 2023, Crown Bioscience, a US-based contract research organization (CRO) and JSR Life Sciences company, launched the OrganoidXplore, a revolutionary large-scale organoid panel screening platform for accelerated preclinical oncology drug discovery. This platform utilizes Crown Bioscience's unique assay-ready (AR) organoid technology, demonstrating highly robust performance, accelerated project timelines, and reduced costs compared to traditional methods. OrganoidXplore provides reliable and reproducible drug response comparisons, offering a significant advancement in preclinical drug screening by accurately replicating the genomic, morphological, and pathophysiological attributes of original tumors.What Are Latest Mergers And Acquisitions In The Organoids Market?
In December 2024, Merck KGaA, a Germany-based life sciences company, acquired HUB Organoids Holding B.V. for an undisclosed amount. Through this acquisition, Merck aims to expand its next-generation biology portfolio by integrating HUB Organoids’ proprietary organoid technology, including model generation, assay development, and high-throughput screening capabilities. HUB Organoids Holding B.V. is a Netherlands-based company that provides organoid technology services and holds foundational patents in organoid biology.Regional Outlook
North America was the largest region in the organoids market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global organoids market size forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.What Defines the Organoids Market?
The organoids market consists of sales of epithelial organoid, embryonic organoid, and cerebral organoid. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.What Key Data and Analysis Are Included in the Organoids Market Report 2026?
The organoids market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the organoids industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Organoids Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $5.9 billion |
| Revenue Forecast In 2035 | $13.13 billion |
| Growth Rate | CAGR of 22.3% from 2026 to 2035 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 - 2035 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2035 |
| Segments Covered | Product, Application, End-User |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, ... |
| Key Companies Profiled | Cellesce Ltd., STEMCELL Technologies, HUB Organoids, DefiniGEN, OcellO B.V., Organoid Therapeutics, InSphero AG, Axol Bioscience Ltd., TissUse GmbH, Epithelix Sàrl, SUN Bioscience, Prellis Biologics, Epistem, MIMETAS BV, Organoidsciences Ltd., Zenit Science, Biomorgan, TheWell Bioscience Inc., CN Bio Innovations Ltd., TARA Biosystems, Nortis Inc., Newcells Biotech, Known Medicine, Dynomics Inc., CHA Biotech Co Ltd, Tempus AI Inc. |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |
